|
1
|
Zhao F, Xu M, Lei H, Zhou Z, Wang L, Li P,
Zhao J and Hu P: Clinicopathological characteristics of patients
with non-small-cell lung cancer who harbor EML4-ALK fusion gene: A
meta-analysis. PLoS One. 10:e01173332015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ou SHI, Zhu VW and Nagasaka M: Catalog of
5′ fusion partners in ALK-positive NSCLC circa 2020. JTO Clin Res
Rep. 1:1000152020.PubMed/NCBI
|
|
3
|
Tao H, Shi L, Zhou A, Li H, Gai F, Huang
Z, Che N and Liu Z: Distribution of EML4-ALK fusion variants and
clinical outcomes in patients with resected non-small cell lung
cancer. Lung Cancer. 149:154–161. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hendriks LE, Kerr KM, Menis J, Mok TS,
Nestle U, Passaro A, Peters S, Planchard D, Smit EF, Solomon BJ, et
al: Oncogene-addicted metastatic non-small-cell lung cancer: ESMO
clinical practice guideline for diagnosis, treatment and follow-up.
Ann Oncol. 34:339–357. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jeon H, Wang S, Song J, Gill H and Cheng
H: Update 2025: Management of non-small-cell lung cancer. Lung.
203:532025. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mok T, Camidge DR, Gadgeel SM, Rosell R,
Dziadziuszko R, Kim DW, Pérol M, Ou SI, Ahn JS, Shaw AT, et al:
Updated overall survival and final progression-free survival data
for patients with treatment-naive advanced ALK-positive
non-small-cell lung cancer in the ALEX study. Ann Oncol.
31:1056–1064. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Solomon BJ, Liu G, Felip E, Mok TSK, Soo
RA, Mazieres J, Shaw AT, de Marinis F, Goto Y, Wu YL, et al:
Lorlatinib versus crizotinib in patients with advanced ALK-positive
non-small cell lung cancer: 5-year outcomes from the phase III
CROWN study. J Clin Oncol. 42:3400–3409. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Canale M, Pasini L, Bronte G, Delmonte A,
Cravero P, Crinò L and Ulivi P: Role of liquid biopsy in
oncogene-addicted non-small cell lung cancer. Transl Lung Cancer
Res. 8 (Suppl 3):S265–S279. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gilson P, Levy J, Rouyer M, Demange J,
Husson M, Bonnet C, Salleron J, Leroux A, Merlin JL and Harlé A:
Evaluation of 3 molecular-based assays for microsatellite
instability detection in formalin-fixed tissues of patients with
endometrial and colorectal cancers. Sci Rep. 10:163862020.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Institut Francophone de Cancérologie
Thoracique (IFCT), . French national guidelines for molecular
testing and precision medicine in thoracic oncology. IFCT; Paris:
2023, https://www.ifct.fr/images/Indication_des_tests_mol%C3%A9culaires_traitements_de_pr%C3%A9cision_Poumon_1.pdfApril
2–2026
|
|
11
|
Gainor JF, Dardaei L, Yoda S, Friboulet L,
Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K,
Singh M, et al: Molecular mechanisms of resistance to first- and
second-generation ALK inhibitors in ALK-rearranged lung cancer.
Cancer Discov. 6:1118–1133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin YT, Yu CJ, Yang JCH and Shih JY:
Anaplastic lymphoma kinase (ALK) kinase domain mutation following
ALK inhibitor(s) failure in advanced ALK positive non-small-cell
lung cancer: Analysis and literature review. Clin Lung Cancer.
17:e77–e94. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Toyokawa G and Seto T: Updated evidence on
the mechanisms of resistance to ALK inhibitors and strategies to
overcome such resistance: Clinical and preclinical data. Oncol Res
Treat. 38:291–298. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Doebele RC, Pilling AB, Aisner DL,
Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ,
Heasley LE, Franklin WA, et al: Mechanisms of resistance to
crizotinib in patients with ALK gene rearranged non-small cell lung
cancer. Clin Cancer Res. 18:1472–1482. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rossing HH, Grauslund M, Urbanska EM,
Melchior LC, Rask CK, Costa JC, Skov BG, Sørensen JB and
Santoni-Rugiu E: Concomitant occurrence of EGFR (epidermal growth
factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog) mutations in an ALK (anaplastic lymphoma
kinase)-positive lung adenocarcinoma patient with acquired
resistance to crizotinib: A case report. BMC Res Notes. 6:4892013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Campos-Gomez S, Lara-Guerra H, Routbort
MJ, Lu X and Simon GR: Lung adenocarcinoma with concurrent KRAS
mutation and ALK rearrangement responding to crizotinib: Case
report. Int J Biol Markers. 30:e254–e257. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Azzato EM, Deshpande C, Aikawa V, Aggarwal
C, Alley E, Jacobs B, Morrissette J and Daber R: Rare complex
mutational profile in an ALK inhibitor-resistant non-small cell
lung cancer. Anticancer Res. 35:3007–3012. 2015.PubMed/NCBI
|
|
18
|
Mengoli MC, Barbieri F, Bertolini F and
Tiseo M: K-RAS mutations indicating primary resistance to
crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of
two cases and review of the literature. Lung Cancer. 93:55–58.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu YC, Wan B, Wu LX, Li XL, Wang WX, Xu
CW, Zhuang W, Wei JG and Du KQ: Dual drive coexistence of ALK
rearrangement and KRAS mutation advanced lung adenocarcinoma and
response to crizotinib. Transl Cancer Res. 8:1630–1634. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kemper M, Evers G, Schulze AB, Sperveslage
J, Schülke C, Lenz G, Herold T, Hartmann W, Schildhaus HU and
Bleckmann A: Polyclonal on- and off-target resistance mutations in
an EML4-ALK positive non-small cell lung cancer patient under ALK
inhibition. Oncotarget. 12:1946–1952. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang N, Qu T, Zhang C and Li J: Case
report: Successful treatment of advanced pulmonary sarcomatoid
carcinoma with BUBIB-ALK rearrangement and KRAS G12C mutation by
sintilimab combined with anlotinib. Front Oncol. 14:12691482024.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lescuyer G, Harlé A, Kumar HS,
Constantoulakis P, Pfarr N, Heitzer E, Michon C, Russo G, Speel EM,
Piecyk M, et al: Analytical validation of a pan-cancer
next-generation sequencing assay for in-house liquid biopsy
testing: An international multicenter study. J Mol Diagn.
27:1174–1188. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gilson P, Pouget C, Belmonte R, Fadil S,
Demange J, Rouyer M, Lacour J, Betz M, Dardare J, Witz A, et al:
Validation of the Idylla GeneFusion assay to detect fusions and MET
exon-skipping in non-small cell lung cancers. Sci Rep.
13:129092023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hua G, Zhang X, Zhang M, Wang Q, Chen X,
Yu R, Bao H, Liu J, Wu X, Shao Y, et al: Real-world circulating
tumor DNA analysis depicts resistance mechanism and clonal
evolution in ALK inhibitor-treated lung adenocarcinoma patients.
ESMO Open. 7:1003372022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ju L, Han M, Zhao C and Li X: EGFR, KRAS
and ROS1 variants coexist in a lung adenocarcinoma patient. Lung
Cancer. 95:94–97. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bazhenova L, Hodgson JG, Camidge DR,
Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD,
et al: Activity of brigatinib in patients with crizotinib-resistant
ALK-positive non-small-cell lung cancer according to ALK fusion and
mutation status. Clin Lung Cancer. 26:e503–e513.e11. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tang Q, Li T, Ren F, Li X, Cao W, Yu H,
Mao F, Cao C, Zu L and Xu S: Response of a novel KANK1::ALK fusion
to alectinib in an advanced lung adenocarcinoma: A case report. J
Natl Compr Canc Netw. 22:e2371072024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang B, Hu L, Dong D, Guo Z, Wei W, Wang
C, Shao W, Ma T, Chen Y, Li Q and Hu W: TP53 or CDKN2A/B
covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a
high TMB, tumor immunosuppressive microenvironment and poor
prognosis. J Cancer Res Clin Oncol. 149:10041–10052. 2023.
View Article : Google Scholar : PubMed/NCBI
|
